Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
about
The steady progress of targeted therapies, promising advances for lung cancerThe Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsSuccesses and Challenges of PARP Inhibitors in Cancer TherapyTargeted Therapies in Triple-Negative Breast CancerHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerTargeting the Checkpoint to Kill Cancer CellsPARP inhibitors in the management of breast cancer: current data and future prospectsThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisActivation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerComplementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.Novel therapeutic strategies for patients with triple-negative breast cancerTriple-negative breast cancer: is there a treatment on the horizon?Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsBRCA1 reversion mutation acquired after treatment identified by liquid biopsy.Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionPoly (ADP-ribose) polymerase inhibitors: recent advances and future development.BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Reverse the Resistance to PARP Inhibitors.Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.Embracing synthetic lethality of novel anticancer therapies.Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.Profiling of the metabolic transcriptome via single molecule molecular inversion probes.ARID1B alterations identify aggressive tumors in neuroblastoma.A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cellsJust like the rest of evolution in Mother Nature, the evolution of cancers may be driven by natural selection, and not by haphazard mutationsBRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.What a 'Ku'incidence!: parallel discoveries of a new DNA repair factor.CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
P2860
Q26746895-661FB1A9-C286-4959-9F78-EE46C66FF70BQ26765247-FACCA034-9C84-4340-A8C4-FC56832F7E91Q26777131-ACA070B6-EDA5-4AA0-B9A9-377FCEF602F5Q26777736-C8B093AD-381A-4EDB-A596-369E96AF5A39Q26783551-68DAD785-4DEA-4C0F-8C83-98A471BE7618Q26795781-ACAA44BF-53A3-4931-AFC7-999639DCBBA8Q26798352-74BD0F69-8A62-403E-9046-B84AD43CCCD7Q26865888-FBFC0774-2927-4516-B9F9-DBBCC7D28982Q27315948-0ED55D9A-AB5B-44F1-9260-371F12B78B71Q27853152-B29CB5CA-9B8A-4977-83CA-D3D76B50E814Q28067436-7B89291F-82C9-4CE1-9FBB-2CBE1CAFB9B6Q28077243-2B89C60C-9679-4F5B-86E2-047E68CD4D10Q30250038-EA01B304-8F8A-4259-9F9E-56E175047400Q33618910-369F66CD-F961-4F68-A171-B0601539CBEEQ33869633-555EF074-DECE-46C6-BC0F-574C94762805Q33917649-2EA762E3-8AB1-46A0-B173-8FFB0E1BC2C1Q35767389-BF209086-49E2-4EA2-8095-420E55B73141Q35895214-DFD8D039-8E36-4CC2-A88F-D935211BEACBQ35909731-8F0D8DD1-EE30-4EBA-9875-151EFDA059D1Q36563979-AA49B5D0-B2A3-4749-960C-6AF0E8DA1A64Q37082160-5789D6CC-944C-495A-9231-CC0C9C56D3ECQ37158437-2B3290A4-5E30-44AE-A384-74EE01536A8DQ37190452-B05F14F5-4C14-4737-8150-B3226A569FA8Q37558633-396AE354-EDF2-4BFD-91CC-B1BD2A373975Q37607283-5C83F655-8C8C-44F2-9BA0-C9B6525422A0Q37634102-A3BF8BE5-8D80-47EB-B1DB-7F7955C051C9Q37675896-E2BE4795-DD41-4248-BA49-FDC95D35F804Q37684589-BEA1D078-6422-473C-931A-707F1299A2BEQ38554530-B3D400BE-11D6-4522-AFE7-66933A810C9AQ38645200-B2FA5D23-88E6-45DA-AE43-CB5EAC1EDB7EQ38683171-AA90344C-27B8-47CE-9727-0A6BC6D29969Q38718686-16008D94-C679-4223-BFC2-5F817A85AC92Q38811820-5AD034A4-62BE-4B86-9CA7-3E343544DC93Q41198110-86214749-5E58-4B9D-A073-409273D98A5EQ41233835-CA88F68A-19D7-41C0-8C40-A1246BC84B6FQ41365343-7320D841-8A5A-47E3-994E-EB4F1ECA8E12Q42236265-1E1943AC-CEA8-4ADB-85CF-A69F81E9CAFEQ42280757-61D1FF48-CA49-4271-A3E5-2D8721164F52Q42566225-251D115A-7EBB-4211-8CEA-6704E62D3722Q43898530-DD993B4B-8CAB-451E-A2C3-F58DCCAE91CA
P2860
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
@en
type
label
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
@en
prefLabel
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
@en
P1476
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
@en
P2093
Jos Jonkers
P304
P356
10.1158/1078-0432.CCR-13-0225
P407
P577
2013-11-22T00:00:00Z